With state-of-the-art drug development platforms and advanced technologies, Creative Biolabs has updated its antiviral drug discovery services, especially neutralizing antibody development for SARS-CoV-2.
— The continuous spread of COVID-19 has become a threat to global health and even has led to a global economic crisis. Researchers arounad the world are putting tremendous effort toward developing vaccines and therapeutic drugs.
Creative Biolabs has been dedicated to the discovery and development of different types of vaccines, including in silico vaccine, live attenuated and killed vaccine, recombinant subunit vaccine, and vaccinia virus vaccine for SARS-CoV-2. Drug discovery is often a laborious, and time‐consuming task. Now, Creative Biolabs has optimized a portfolio of antiviral drug discovery services, especially neutralizing antibody development for SARS-CoV-2.
As one of the well-recognized experts who are professional in antibody development, Creative Biolabs has built a variety of antibody development platforms, which can support phage display & antibody library services, custom antibody & hybridoma services, in vitro display services, etc. To advance the drug discovery for SARS-CoV-2, scientists at Creative Biolabs are committed to neutralizing antibody development mainly through the following subjects.
· CR3022 as A Target for SARS-CoV-2 Antibody Development
Research has demonstrated that a SARS-CoV specific human mAb, CR3022, could bind potently with the RBD of SARS-CoV-2, which creates an opportunity that CR3022 compound would facilitate the first therapeutic strategies for COVID-19. Creative Biolabs offers time-saving, cost-effective services to tailor the most appropriate strategies by virtue of CR3022.
· CD4 as A Target for SARS-CoV-2 Antibody Development
Ibalizumab has been approved by the Food and Drug Administration to treat HIV/AIDS, and it has been studied recently to be a potential treatment for SARS-CoV-2. Creative Biolabs provides one-stop services to assist customers in developing high-quality antibody medicines directing CD4 target.
· Glycoprotein as a Target for SARS-CoV-2 Antibody Development
Research found that mAb114, a monoclonal antibody targeting the Ebola virus glycoprotein, is well tolerated, shows linear pharmacokinetics, and thus is an attractive and deployable option for treatment in outbreak settings. Glycoprotein maybe a potential target for SARS-CoV-2 antibody discovery, and Creative Biolabs is dedicated to helping clients in the antibody discovery process of SARS-CoV-2.
In addition to this neutralizing antibody development, Creative Biolabs’ antiviral drug discovery services also cover inhibitors of host cell protease (darunavir and lopinavir for SARS-CoV-2), viral protease inhibitors, nucleoside analogue inhibitors, RNA synthesis inhibitors, antiviral peptide, broad-spectrum antiviral drugs, anti-inflammatory drugs, aptamers, complement therapy, etc.
More information can be found on https://sars-cov-2.creative-biolabs.com/.
About Creative Biolabs
Empowered by leading technology and over 15 years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.
Release ID: 88995450